Proteolytic Processing Regulates Toll-like Receptor 3 Stability and Endosomal Localization

被引:76
|
作者
Qi, Rongsu [1 ]
Singh, Divyendu [1 ]
Kao, C. Cheng [1 ]
机构
[1] Indiana Univ, Dept Mol & Cellular Biochem, Bloomington, IN 47401 USA
关键词
DOUBLE-STRANDED-RNA; MONOCLONAL-ANTIBODY; DENDRITIC CELLS; NUCLEIC-ACID; BINDING-SITE; TLR3; RECOGNITION; ACTIVATION; UNC93B1; DNA;
D O I
10.1074/jbc.M112.387803
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Toll-like receptors (TLRs) 3, 7, and 9 are innate immune receptors that recognize nucleic acids from pathogens in endosomes and initiate signaling transductions that lead to cytokine production. Activation of TLR9 for signaling requires proteolytic processing within the ectodomain by endosome-associated proteases. Whether TLR3 requires similar proteolytic processing to become competent for signaling remains unclear. Herein we report that human TLR3 is proteolytically processed to form two fragments in endosomes. Unc93b1 is required for processing by transporting TLR3 through the Golgi complex and to the endosomes. Proteolytic cleavage requires the eight-amino acid Loop1 within leucine-rich repeat 12 of the TLR3 ectodomain. Proteolytic cleavage is not required for TLR3 signaling in response to poly(I:C), although processing could modulate the degree of response toward viral double-stranded RNAs, especially in mouse cells. Both the full-length and cleaved fragments of TLR3 can bind poly(I:C) and are present in endosomes. However, although the full-length TLR3 has a half-life in HEK293T cells of 3 h, the cleaved fragments have half-lives in excess of 7 h. Inhibition of TLR3 cleavage by either treatment with cathepsin inhibitor or by a mutation in Loop1 decreased the abundance of TLR3 in endosomes targeted for lysosomal degradation.
引用
收藏
页码:32617 / 32629
页数:13
相关论文
共 50 条
  • [21] Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists
    Torres Andon, Fernando
    Leon, Sergio
    Ummarino, Aldo
    Redin, Esther
    Allavena, Paola
    Serrano, Diego
    Anfray, Clement
    Calvo, Alfonso
    BIOMEDICINES, 2022, 10 (07)
  • [22] Toll-like receptor 2 signaling regulates the tubercle granuloma
    McBride, Amanda
    Salgame, Padmini
    JOURNAL OF IMMUNOLOGY, 2011, 186
  • [23] Toll-like receptor 7 regulates pancreatic inflammation and transformation
    Graffeo, Christopher S.
    Rehman, Adeel
    Zambirinis, Constantinos P.
    Henning, Justin R.
    Fallon, Nina
    Barilla, Rocky
    Medina-Zea, Marco V.
    Jamal, Mohsin
    Deutsch, Michael
    Miller, George
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2012, 215 (03) : S16 - S16
  • [24] Toll-like receptor 7 regulates osteoclastogenesis in rheumatoid arthritis
    Kim, Kyoung-Woon
    Kim, Bo-Mi
    Won, Ji-Yeon
    Lee, Kyung-Ann
    Kim, Hae-Rim
    Lee, Sang-Heon
    JOURNAL OF BIOCHEMISTRY, 2019, 166 (03): : 259 - 270
  • [25] The role of toll-like receptor 3 in epilepsy
    Benninger, F.
    Gross, A.
    Steiner, I.
    Offen, D.
    Okun, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 63 - 63
  • [26] Toll-like receptor 3 mediates a more potent antiviral response than toll-like receptor 4
    Doyle, SE
    O'Connell, R
    Vaidya, SA
    Chow, EK
    Yee, K
    Cheng, GH
    JOURNAL OF IMMUNOLOGY, 2003, 170 (07): : 3565 - 3571
  • [27] Toll-Like Receptor 3 in Cardiovascular Diseases
    Zhuang, Chunying
    Chen, Riken
    Zheng, Zhenzhen
    Lu, Jianmin
    Hong, Cheng
    HEART LUNG AND CIRCULATION, 2022, 31 (07): : E93 - E109
  • [28] THE ROLE OF TOLL-LIKE RECEPTOR 3 IN EPILEPSY
    Benninger, F.
    Gross, A.
    Steiner, I
    Offen, D.
    Okun, E.
    EPILEPSIA, 2014, 55 : 8 - 9
  • [29] Toll-Like Receptor 3 in Liver Diseases
    Yin, Shi
    Gao, Bin
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2010, 2010
  • [30] Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood
    De Wit, D
    Tonon, S
    Olislagers, V
    Goriely, S
    Boutriaux, M
    Goldman, M
    Willems, F
    JOURNAL OF AUTOIMMUNITY, 2003, 21 (03) : 277 - 281